Individualized Answers For Patients With Breast Cancer EndoPredict® provides accurate results for patients diagnosed with ER+, HER2−, early-stage breast cancer with either node-negative or node-positive disease (1- 3 nodes). The test combines a 12-gene molecular score (tumor biology) with tumor size and nodal status (tumor pathology) to significantly improve prognostic performance over the leading competitor. … EndoPredict Read More »